MethodsThe experimental study was conducted. Hepatocellular carcinoma MHCC97-H and Huh7 cells and human umbilical vein endothelial cells (HUVEC) were cultured in vitro. Each cell line was divided into 3 groups: control group (non-treated), low concentration group (treated using 1 μmol/L T0901317) and high concentration group (treated using 3 μmol/L T0901317). Cell proliferation was counted with a CCK-8 assay. Quantitative real-time polymerase chain reaction (PCR) was applied to confirm the relative mRNA expression of fatty acid synthetase (FAS) of liver X receptor target genes in 3 groups. Subcutaneous xenograft tumor volume and body mass were measured in MHCC97-H nude mice model. Then mice were sacrificed and tumor tissues were analyzed for CD31 relative expression by immunohistochemistry (IHC) staining. Migration and vessel angiogenesis of HUVEC were determined by Transwell method. Observation indicators: (1) effects of T0901317 on MHCC97-H, Huh7 and HUVEC cells proliferation, (2) effects of T0901317 on liver X receptor with MHCC97-H, Huh7 and HUVEC cells, (3) effects of T0901317 on subcutaneous xenograft tumor growth in MHCC97-H nude mice model, (4) effects of T0901317 on CD31 relative expression in subcutaneous xenograft tumor tissues of MHCC97-H nude mice model, (5) effects of T0901317 on migration of HUVEC, (6) effects of T0901317 on vessel angiogenesis of HUVEC. Measurement data with normal distribution were represented as 
±s, and comparisons between groups were analyzed by the t test.
Results(1) Effects of T0901317 on MHCC97-H, Huh7 and HUVEC cells proliferation: results of CCK-8 assay showed that percentage of living cells was respectively 100.0%±1.7%, 101.0%±0.7% and 104.6%±1.9% in MHCC97-H control, low concentration and high concentration groups, with no statistically significant difference (F=2.632, P>0.05). Percentage of living cells was respectively 100.0%±2.7%, 97.6%±2.4% and 103.7%±2.8% in Huh7 control, low concentration and high concentration groups, with no statistically significant difference (F=1.404, P>0.05). Percentage of living cells was respectively 100.0%±0.7%, 100.7%±1.2% and 101.3%±0.8% in HUVEC control, low concentration and high concentration groups, with no statistically significant difference (F=0.471, P>0.05). (2) Effects of T0901317 on liver X receptor with MHCC97-H, Huh7 and HUVEC cells: results of quantitative real-time PCR showed that relative mRNA expressions of FAS in MHCC97-H control, low concentration and high concentration groups were respectively 100.0 %±2.2%, 658.5%±7.7% and 1 241.0%±106.8%, with a statistically significant difference among groups (F=46.227, P<0.05), and with a statistically significant difference between MHCC97-H control group and MHCC97-H low concentration and high concentration groups (t=70.025, 8.274, P<0.05) and between MHCC97-H low concentration and high concentration groups (t=4.222, P<0.05). Relative mRNA expressions of FAS in Huh7 control, low concentration and high concentration groups were respectively 100.0%±15.8%, 1 225.0%±26.7% and 2 015.0%±215.1%, with a statistically significant difference among groups (F=49.402, P<0.05), and with a statistically significant difference between Huh7 control group and Huh7 low concentration and high concentration groups (t=39.460, 8.879, P<0.05) and between Huh7 low concentration and high concentration groups (t=2.836, P<0.05). Relative mRNA expressions of FAS in HUVEC control, low concentration and high concentration groups were respectively 100.0%±19.6%, 790.8%±116.5% and 1 756.0%±55.0%, with a statistically significant difference among groups (F=185.395, P<0.05), and with a statistically significant difference between HUVEC control group and HUVEC low concentration and high concentration groups (t=7.639, 34.375, P<0.05) and between HUVEC low concentration and high concentration groups (t=7.488, P<0.05). (3) Effects of T0901317 on subcutaneous xenograft tumor growth in MHCC97-H nude mice model: results of assay showed that subcutaneous xenograft tumor volume in MHCC97-H control group and MHCC97-H T0901317 group were respectively (935±72)mm3 and (552±47)mm3, with a statistically significant difference between groups (t=4.449, P<0.05). Body masses of nude mice model in MHCC97-H control group and MHCC97-H T0901317 group were respectively (23.8±0.8)g and (21.7±1.7)g, with no statistically significant difference between groups (t=1.059, P>0.05). (4) Effects of T0901317 on CD31 relative expression in subcutaneous xenograft tumor tissues of MHCC97-H nude mice model: results of IHC staining showed that CD31 relative expression in subcutaneous xenograft tumor tissues of MHCC97-H nude mice model was 100%±11% and 35%±7% in MHCC97-H control group and MHCC97-H T0901317 group, with a statistically significant difference between groups (t=4.919, P<0.05). (5) Effects of T0901317 on migration of HUVEC: results of Transwell method showed that percentages of membrane cells in HUVEC control, low concentration and high concentration groups were respectively 100.0%±4.0%, 57.3%±1.5% and 32.7%±1.7%, with a statistically significant difference among groups (F=163.944, P<0.05), and with statistically significant differences between HUVEC control group and HUVEC low concentration and high concentration groups (t=9.998, 15.434, P<0.05) and between HUVEC low concentration and high concentration groups (t=10.801, P<0.05). (6) Effects of T0901317 on vessel angiogenesis of HUVEC: results of vessel angiogenesis assay showed that length of vessel angiogenesis in HUVEC control, low concentration and high concentration groups were respectively 100.0%±3.4%, 68.4%±3.5% and 44.7%±0.5%, with a statistically significant difference among groups (F=38.964, P<0.05), and with statistically significant differences between HUVEC control group and HUVEC low concentration and high concentration groups (t=6.268, 9.831, P<0.05) and between HUVEC low concentration and high concentration groups (t=3.460, P<0.05).
±s表示，多组间比较采用方差分析，两组间比较采用t检验。
